|
Other - Net, Expense (Income) (Details) (USD $)
In Millions, unless otherwise specified |
3 Months Ended | 12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2013
|
Sep. 30, 2013
|
Jun. 30, 2013
|
Mar. 31, 2013
|
Dec. 31, 2012
|
Sep. 30, 2012
|
Jun. 30, 2012
|
Mar. 31, 2012
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
|
| Other Revenue, Net | $ 707.5 | $ 633.0 | $ 681.7 | ||||||||
| Income related to termination of the exenatide collaboration with Amylin | (495.4) | (787.8) | 0 | ||||||||
| Interest Expense | 160.1 | 177.8 | 186.0 | ||||||||
| Investment Income, Interest | (119.7) | (105.0) | (79.9) | ||||||||
| Other (income)expense | (63.9) | 41.0 | 72.9 | ||||||||
| Nonoperating Income (Expense), Total | (9.1) | 31.3 | (11.9) | (529.2) | 52.0 | (788.5) | 16.5 | 46.0 | (518.9) | (674.0) | 179.0 |
|
Exenatide [Member]
|
|||||||||||
| Other Revenue, Net | 0 | 70.1 | 243.1 | ||||||||
| Other (income)expense | $ (495.4) | ||||||||||